Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Stock Now Rated “Hold” by Wall Street Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been given an average recommendation of “Hold” by the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $24.80.

A number of brokerages recently issued reports on ARTV. Jefferies Financial Group downgraded shares of Artiva Biotherapeutics from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a report on Thursday, October 29th. Needham & Company LLC lowered shares of Artiva Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 27th. TD Cowen lowered Artiva Biotherapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 27th. HC Wainwright reaffirmed a “buy” rating on shares of Artiva Biotherapeutics in a report on Friday, October 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $40.00 price target on shares of Artiva Biotherapeutics in a research report on Friday, October 2nd.

Insider Buying and Selling at Artiva Biotherapeutics

In other news, insider Subhashis Banerjee sold 8,222 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $12.01, for a total value of $98,746.22. Following the completion of the sale, the insider directly owned 142,047 shares in the company, valued at $1,705,984.47. This represents a 5.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Jennifer Bush sold 8,370 shares of Artiva Biotherapeutics stock in a transaction on Monday, October 5th. The stock was sold at an average price of $6.84, for a total value of $57,250.80. Following the transaction, the chief operating officer owned 366,159 shares in the company, valued at approximately $2,504,527.56. This represents a 2.23% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 137,048 shares of company stock worth $1,086,167 in the last quarter. Insiders own 1.80% of the company’s stock.

Institutional Trading of Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. State of Wyoming acquired a new position in Artiva Biotherapeutics during the 2nd quarter worth about $45,000. Squarepoint Ops LLC acquired a new position in Artiva Biotherapeutics in the 2nd quarter valued at about $144,000. Spark Investment Management LLC purchased a new stake in Artiva Biotherapeutics during the second quarter worth about $160,000. Dimensional Fund Advisors LP purchased a new stake in Artiva Biotherapeutics during the first quarter worth about $131,000. Finally, Sanctuary Advisors LLC acquired a new stake in shares of Artiva Biotherapeutics during the first quarter worth about $139,000.

Artiva Biotherapeutics Stock Performance

ARTV stock traded up $0.02 during midday trading on Friday, reaching $4.15. The stock had a trading volume of 908,474 shares, compared to its average volume of 1,152,021. The firm has a fifty day simple moving average of $7.37 and a two-hundred day simple moving average of $7.95. The stock has a market cap of $202.89 million, a PE ratio of -1.26 and a beta of 2.67. Artiva Biotherapeutics has a 52-week low of $2.96 and a 52-week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its earnings results on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, hitting the consensus estimate of ($0.63). On average, sell-side analysts predict that Artiva Biotherapeutics will post -2.71 EPS for the current fiscal year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is intended to provide readily available cell-based treatments that can be manufactured in advance and administered without using each patient’s own cells.

Artiva’s lead product candidate is AlloNK, also known as AB-101, an allogeneic NK cell therapy derived from umbilical cord blood. The company is evaluating AlloNK in combination with antibody treatments, including rituximab, for conditions such as B-cell malignancies and autoimmune diseases.